AURORA CANNABIS (21P.F)
| Previous Close | 6.70 |
| Open | 6.64 |
| Bid | 6.28 x N/A |
| Ask | 6.30 x N/A |
| Day's Range | 6.22 - 6.65 |
| 52 Week Range | 0.34 - 10.78 |
| Volume | |
| Avg. Volume | 21,978 |
| Market Cap | 347.961M |
| Beta (5Y Monthly) | 2.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Aurora Cannabis Commends Germany's Landmark Legalization Achievement
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – a Canadian based leading global medical cannabis company, applauds the German government's final endorsement of cannabis legalization, marking a significant step forward in bolstering patient access to medical cannabis with the official passing of the Cannabis Act.
- CNW Group
Aurora Cannabis Achieves Australia's TGA GMP Certification, Setting Global Standard for Quality and Compliance
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company has received Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA) for its Canadian production facilities, River and Ridge. The TGA is responsible for regulating the supply, import, export, manufacturing and advertising of therapeutic goods in Australia. Obtaining TGA's GMP certification enables the company to deliver top-tier cannabis produ
- CNW Group
Aurora Introduces Medical Cannabis Pastilles for Patient Relief in Australia
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company, together with subsidiary company, MedReleaf Australia, have announced today the availability of medical cannabis pastilles for doctors to prescribe to patients in Australia. The novel product is produced by Aurora and distributed by MedReleaf Australia, a leading distributor of medical cannabis products with the number two position in the Australian market.
